Author Title Type [ Year(Asc)]
Filters: Author is Kharfan-Dabaja, Mohamed A  [Clear All Filters]
Brow D, Shike H, Kendrick J, Pettersson L, Mineishi S, Claxton DF, Wirk B, Cioccio J, Greiner RJ, Viswanatha D, et al. Assessment of chimerism by next generation sequencing: A comparison to STR/qPCR methods. Hum Immunol. 2024:110794.
Hashmi H, Kumar A, Kharfan-Dabaja MA, Munshi PN, Inamoto Y, DeFilipp ZM, Dholaria B, Jain T, Perales M-A, Carpenter PA, et al. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy. Transplant Cell Ther. 2024.
Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JVillasboas, Rosenthal A, et al. Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy. Haematologica. 2024.
Alyamany R, Fakih REl, Alnughmush A, Albabtain A, Kharfan-Dabaja MA, Aljurf M. A comprehensive review of the role of bone marrow biopsy and PET-CT in the evaluation of bone marrow involvement in adults newly diagnosed with DLBCL. Front Oncol. 2024;14:1301979.
Sureda A, Carpenter PA, Bacigalupo A, Bhatt VRaj, De La Fuente J, Ho A, Kean L, Lee JWook, Sánchez-Ortega I, Savani BN, et al. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transplant. 2024.
Iqbal M, Kharfan-Dabaja MA. Cogent data on allogeneic haematopoietic stem-cell transplantation efficacy in advanced cutaneous T-cell lymphoma. Lancet. 2023.
Acosta-Medina AA, Baranwal A, Johnson IMcKerrow, Kharfan-Dabaja MA, Murthy H, Palmer JM, Sproat L, Mangaonkar A, Shah MV, Hogan WJ, et al. Comparison of Pretransplant Prediction Models for Non-Relapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023.
Ragon BKnick, Shah MVinod, D'Souza A, Estrada-Merly N, Gowda L, George G, DeLima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, et al. Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis. Blood Adv. 2023.
Badar T, Alkhateeb H, Aljurf M, Kharfan-Dabaja MA. Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era. Curr Res Transl Med. 2023;71(2):103392.
Bashir Q, Braunstein M, Buck T, Chmielewski C, Hartmann B, Janakiram M, McMahon MA, Romundstad L, Steele L, Usmani S, et al. Overcoming Barriers to Autologous Stem Cell Transplantation in Multiple Myeloma: Recommendations from a Multidisciplinary Roundtable Discussion. Transplant Cell Ther. 2023.
Kharfan-Dabaja MA, Roy V, Murthy H, Fischer D, Mohty R, Greathouse A, Brown A, Moreno K, Godsey E, Higginbotham JM, et al. Post-Autologous Hematopoietic Cell Transplant Care in the "Home Sweet Home" Setting: A Treatment Paradigm Shift. Hematol Oncol Stem Cell Ther. 2023;16(4):407-411.
Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, Bramanti S, Itälä-Remes M, Schmid C, Busca A, et al. Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of th. Hemasphere. 2023;7(7):e920.
Tamari R, McLornan DP, Ahn KWoo, Estrada-Merly N, Hernández-Boluda JCarlos, Giralt SA, Palmer JM, Gale RPeter, DeFilipp Z, Marks D, et al. A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Blood Adv. 2023.
Ahmed N, Kumar A, Kharfan-Dabaja MA, DeFilipp Z, Herrera A, Hashmi S, Dholaria B, Perales M-A, Carpenter PA, Hamadani M. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after failure of Chimeric antigen receptor T cell therapy (CAR-T) therapy. Transplant Cell Ther. 2022.
Vanegas YM, Mohty R, Gadd ME, Luo Y, Aljurf M, Qin H, Kharfan-Dabaja MA. CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19. Hematol Oncol Stem Cell Ther. 2022;15(3):81-93.
Kharfan-Dabaja MA, Reljic T, Yassine F, Nishihori T, Kumar A, Tawk MM, Keller K, Ayala E, Savani B, Mohty M, et al. Efficacy of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia: results of a systematic review and meta-analysis. Transplant Cell Ther. 2022.
Mohty R, Moustafa MAlhaj, Aljurf M, Murthy H, Kharfan-Dabaja MA. Emerging Role of Autologous CD19 CAR T-Cell Therapies in the Second-Line Setting for Large B-cell Lymphoma: A Game Changer?. Hematol Oncol Stem Cell Ther. 2022;15(3):73-80.
Murthy HS, Yassine F, Iqbal M, Alotaibi S, Moustafa MAlhaj, Kharfan-Dabaja MA. Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?. Hematol Oncol Stem Cell Ther. 2022;15(3):100-111.
Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, Konopleva MY, Frankel AE, Gupta V, Mesa RA, et al. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. Blood. 2022.
Murthy HS, Ahn KWoo, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2022.
Tun AM, Maliske S, Wang Y, Inwards DJ, Habermann TM, Micallef I, Porrata L, Paludo J, Bisneto JVillasboas, Rosenthal A, et al. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Transplant Cell Ther. 2022.
Alseraihy A, McGrath E, Niederwieser D, Chabannon C, Szer J, Mohty M, Kharfan-Dabaja MA, Orchard K, Schwartz J, Rasheed W, et al. WBMT Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. Transplant Cell Ther. 2022.